Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL MATERNAL HEALTH MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL MATERNAL HEALTH MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL MATERNAL HEALTH MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S 5 FORCES
5.3 GLOBAL MATERNAL HEALTH MARKET ANALYSIS
6 EPIDEMOLOGY
6.1 EPIDEMOLOGY OF POST-PARTUM HEMORRHAGING
6.2 EPIDEMOLOGY OF PRE-ECLAMPSIA / ECLAMPSIA
7 INDUSTRY INSIGHTS
7.1 DEMOGRAPHIC TRENDS
7.2 KEY PRICING STRATEGIES
7.3 KEY PATIENT ENROLLMENT STRATEGIES
7.4 INTERVIEWS WITH MANUFACTURING COMPANIES
7.5 OTHER KOL SNAPSHOTS
8 REGULATORY FRAMWORK
9 GLOBAL MATERNAL HEALTH MARKET, BY STAGES
9.1 OVERVIEW
9.2 PREGNANCY
9.3 INTRAUTERINE
9.4 ECTOPIC
9.5 TUBAL
9.6 CHILDBIRTH
9.6.1 VAGINAL DELIVERY
9.6.2 CESARIAN SECTION
9.7 POSTNATAL PERIOD
9.7.1 REGULAR CHILD CHECK UP
9.7.1.1. HEAD TO TOE PHYSICAL EXAMINATION.
9.7.1.2. DEVELOPMENTAL SCREENING.
9.7.1.3. VISION SCREENING.
9.7.1.4. HEARING SCREENING.
9.7.1.5. BLOOD PRESSURE SCREENING.
9.7.1.6. ANAEMIA SCREENING.
9.7.1.7. URINALYSIS.
9.7.1.8. OTHERS
9.7.2 IMMUNIZATIONS
9.7.3 BALANCED DIET
9.7.4 PREVENT POSTPARTUM COMPLICATIONS
9.7.5 RESTORE THE MOTHER TO OPTIMAL HEALTH
9.7.6 ENSURE PROBLEM-FREE BREASTFEEDING
9.8 RISK IN PREGNANCY
9.8.1 HGH
9.8.1.1. MISCARRIAGE
9.8.1.2. PREMATUTRE LABOUR
9.8.2 MOLAR
9.8.2.1. MISCARRIAGE
9.8.2.2. PREMATUTRE LABOUR
10 GLOBAL MATERNAL HEALTH MARKET, BY PRODUCT
10.1 OVERVIEW
10.2 HORMONES
10.2.1 OXYTOCIN
10.2.1.1. INJECTABLE
10.2.1.1.1. MARKET VOLUME (USD MILLION)
10.2.1.1.2. MARKET VOLUME(IU)
10.2.1.1.3. MARKET ASP (USD)
10.2.1.2. NASAL SPRAY
10.2.1.2.1. MARKET VOLUME (USD MILLION)
10.2.1.2.2. MARKET VOLUME(IU)
10.2.1.2.3. MARKET ASP (USD)
10.2.2 MISOPROSTOL
10.2.2.1. VAGINAL
10.2.2.1.1. MARKET VOLUME (USD MILLION)
10.2.2.1.2. MARKET VOLUME(IU)
10.2.2.1.3. MARKET ASP (USD)
10.2.2.1.4. ORAL MARKET VOLUME (USD MILLION)
10.2.2.1.5. MARKET VOLUME(IU)
10.2.2.1.6. MARKET ASP (USD)
10.2.3 OTHERS
10.3 NUTRITIVES
10.3.1 CALCIUM GLUCONATE
10.3.1.1. MARKET VOLUME (USD MILLION)
10.3.1.2. MARKET VOLUME(IU)
10.3.1.3. MARKET ASP (USD)
10.3.2 MAGNESIUM SULFATE
10.3.2.1. MARKET VOLUME (USD MILLION)
10.3.2.2. MARKET VOLUME(IU)
10.3.2.3. MARKET ASP (USD)
10.3.3 SODIUM CHLORIDE
10.3.3.1. MARKET VOLUME (USD MILLION)
10.3.3.2. MARKET VOLUME(IU)
10.3.3.3. MARKET ASP (USD)
10.3.4 SODIUM LACTATE
10.3.4.1. MARKET VOLUME (USD MILLION)
10.3.4.2. MARKET VOLUME(IU)
10.3.4.3. MARKET ASP (USD)
10.3.5 ZINC
10.3.5.1. MARKET VOLUME (USD MILLION)
10.3.5.2. MARKET VOLUME(IU)
10.3.5.3. MARKET ASP (USD)
10.3.6 VITAMIN A
10.3.6.1. MARKET VOLUME (USD MILLION)
10.3.6.2. MARKET VOLUME(IU)
10.3.6.3. MARKET ASP (USD)
10.3.7 OTHERS
10.4 ANALGESICS
10.4.1 DEXAMETHASONE
10.4.1.1. MARKET VOLUME (USD MILLION)
10.4.1.2. MARKET VOLUME(IU)
10.4.1.3. MARKET ASP (USD)
10.4.2 NIFEDIPINE
10.4.2.1. MARKET VOLUME (USD MILLION)
10.4.2.2. MARKET VOLUME(IU)
10.4.2.3. MARKET ASP (USD)
10.4.3 MORPHINE
10.4.3.1. MARKET VOLUME (USD MILLION)
10.4.3.2. MARKET VOLUME(IU)
10.4.3.3. MARKET ASP (USD)
10.4.4 PARACETAMOL
10.4.4.1. MARKET VOLUME (USD MILLION)
10.4.4.2. MARKET VOLUME(IU)
10.4.4.3. MARKET ASP (USD)
10.4.5 OTHERS
10.5 ANTI-INFECTIVES
10.5.1 BENZATHINE
10.5.1.1. MARKET VOLUME (USD MILLION)
10.5.1.2. MARKET VOLUME(IU)
10.5.1.3. MARKET ASP (USD)
10.5.2 GENTAMICIN
10.5.2.1. MARKET VOLUME (USD MILLION)
10.5.2.2. MARKET VOLUME(IU)
10.5.2.3. MARKET ASP (USD)
10.5.3 CEFIXIME
10.5.3.1. MARKET VOLUME (USD MILLION)
10.5.3.2. MARKET VOLUME(IU)
10.5.3.3. MARKET ASP (USD)
10.5.4 METRONIDAZOLE
10.5.4.1. MARKET VOLUME (USD MILLION)
10.5.4.2. MARKET VOLUME(IU)
10.5.4.3. MARKET ASP (USD)
10.5.5 CEFTRIAXONE
10.5.5.1. MARKET VOLUME (USD MILLION)
10.5.5.2. MARKET VOLUME(IU)
10.5.5.3. MARKET ASP (USD)
10.5.6 AMPICILLIN
10.5.6.1. MARKET VOLUME (USD MILLION)
10.5.6.2. MARKET VOLUME(IU)
10.5.6.3. MARKET ASP (USD)
10.5.7 AZITHROMYCIN
10.5.7.1. MARKET VOLUME (USD MILLION)
10.5.7.2. MARKET VOLUME(IU)
10.5.7.3. MARKET ASP (USD)
10.5.8 OTHERS
10.6 VACCINES
10.6.1 INFLUENZA VACCINE
10.6.1.1. MARKET VOLUME (USD MILLION)
10.6.1.2. MARKET VOLUME(IU)
10.6.1.3. MARKET ASP (USD)
10.6.2 DTWP /DTAP1, HIB-1, IPV-1, HEP B2, PCV 1,ROTA-1
10.6.2.1. MARKET VOLUME (USD MILLION)
10.6.2.2. MARKET VOLUME(IU)
10.6.2.3. MARKET ASP (USD)
10.6.3 DTWP /DTAP2, HIB-2, IPV-2, HEP B3, PCV 2, ROTA-2
10.6.3.1. MARKET VOLUME (USD MILLION)
10.6.3.2. MARKET VOLUME(IU)
10.6.3.3. MARKET ASP (USD)
10.6.4 DTWP /DTAP3, HIB-3, IPV-3, HEP B4, PCV 3, ROTA-3
10.6.4.1. MARKET VOLUME (USD MILLION)
10.6.4.2. MARKET VOLUME(IU)
10.6.4.3. MARKET ASP (USD)
10.6.5 BCG VACCINE
10.6.5.1. MARKET VOLUME (USD MILLION)
10.6.5.2. MARKET VOLUME(IU)
10.6.5.3. MARKET ASP (USD)
10.6.6 MMR (MUMPS, MEASLES, RUBELLA)
10.6.6.1. MARKET VOLUME (USD MILLION)
10.6.6.2. MARKET VOLUME(IU)
10.6.6.3. MARKET ASP (USD)
10.6.7 OTHERS
10.7 SERVICES
10.7.1 FETAL HAERTH RATE MONITORING
10.7.2 PORTABLE CARDIOTOCOGRAPHY
10.7.3 PREGNANCY SIMULATOR
10.7.4 BREAST FEEDING MONITORING
10.7.5 VIRTUAL COACHING
10.7.6 TELEMEDICINE
10.7.7 OTHERS
10.8 OTHERS
11 GLOBAL MATERNAL HEALTH MARKET, BY APPLICATION
11.1 OVERVIEW
11.2 POST-PARTUM HEMORRHAGING
11.3 PRE-ECLAMPSIA / ECLAMPSIA
11.4 MALARIA
11.5 MATERNAL SEPSIS
11.6 PRE-TERM BIRTH
11.7 PNEUMONIA
11.8 DIARRHOEA
11.9 VITAMIN A DEFICIENCY
11.1 NEONATAL SEPSIS
11.11 PALLIATIVE CARE
11.12 OTHERS
12 GLOBAL MATERNAL HEALTH MARKET, BY ROUTE OF ADMINISTRATION
12.1 OVERVIEW
12.2 ORAL
12.2.1 TABLET
12.2.2 CAPSULES
12.2.3 LIQUID
12.3 PARENTERAL
12.3.1 POWDER
12.3.2 LIQUID
12.4 OTHERS
13 GLOBAL MATERNAL HEALTH MARKET, BY MODE OF PRESCRIPTION
13.1 OVERVIEW
13.2 PRESCRIPTION
13.3 OVER THE COUNTER
14 GLOBAL MATERNAL HEALTH MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 SPECIALTY CLINICS
14.4 HOME HEALTHCARE
14.5 OTHERS
15 GLOBAL MATERNAL HEALTH MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 DIRECT TENDER
15.3 RETAIL SALES
15.3.1 HOSPITAL PHARMACY
15.3.2 RETAIL PHARMACY
15.3.3 ONLINE PHARMACY
15.4 OTHERS
16 GLOBAL MATERNAL HEALTH MARKET, BY REGION
16.1 GLOBAL MATERNAL HEALTH MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
16.2 NORTH AMERICA
16.2.1 U.S.
16.2.2 CANADA
16.2.3 MEXICO
16.3 EUROPE
16.3.1 GERMANY
16.3.2 FRANCE
16.3.3 U.K.
16.3.4 ITALY
16.3.5 SPAIN
16.3.6 RUSSIA
16.3.7 TURKEY
16.3.8 BELGIUM
16.3.9 NETHERLANDS
16.3.10 SWITZERLAND
16.3.11 REST OF EUROPE
16.4 ASIA-PACIFIC
16.4.1 JAPAN
16.4.2 CHINA
16.4.3 SOUTH KOREA
16.4.4 INDIA
16.4.5 AUSTRALIA
16.4.6 SINGAPORE
16.4.7 THAILAND
16.4.8 MALAYSIA
16.4.9 INDONESIA
16.4.10 PHILIPPINES
16.4.11 REST OF ASIA-PACIFIC
16.5 SOUTH AMERICA
16.5.1 BRAZIL
16.5.2 ARGENTINA
16.5.3 REST OF SOUTH AMERICA
16.6 MIDDLE EAST AND AFRICA
16.6.1 SOUTH AFRICA
16.6.2 SAUDI ARABIA
16.6.3 UAE
16.6.4 EGYPT
16.6.5 ISRAEL
16.6.6 REST OF MIDDLE EAST AND AFRICA
16.7 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
17 GLOBAL MATERNAL HEALTH MARKET, COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: GLOBAL
17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
17.3 COMPANY SHARE ANALYSIS: EUROPE
17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
17.5 MERGERS & ACQUISITIONS
17.6 NEW PRODUCT DEVELOPMENT & APPROVALS
17.7 EXPANSIONS
17.8 REGULATORY CHANGES
17.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
18 GLOBAL MATERNAL HEALTH MARKET, COMPANY PROFILE
18.1 ELI LILLY AND COMPANY
18.1.1 COMPANY OVERVIEW
18.1.2 REVENUE ANALYSIS
18.1.3 GEOGRAPHIC PRESENCE
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENTS
18.2 THERAPEUTICSMD, INC
18.2.1 COMPANY OVERVIEW
18.2.2 REVENUE ANALYSIS
18.2.3 GEOGRAPHIC PRESENCE
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPEMENTS
18.3 GLAXOSMITHKLINE PLC
18.3.1 COMPANY OVERVIEW
18.3.2 REVENUE ANALYSIS
18.3.3 GEOGRAPHIC PRESENCE
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPEMENTS
18.4 DR. REDDY’S LABORATORIES LTD.
18.4.1 COMPANY OVERVIEW
18.4.2 REVENUE ANALYSIS
18.4.3 GEOGRAPHIC PRESENCE
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPEMENTS
18.5 JOHNSON & JOHNSON SERVICES, INC.
18.5.1 COMPANY OVERVIEW
18.5.2 REVENUE ANALYSIS
18.5.3 GEOGRAPHIC PRESENCE
18.5.4 PRODUCT PORTFOLIO
18.5.5 RECENT DEVELOPEMENTS
18.6 PFIZER INC.
18.6.1 COMPANY OVERVIEW
18.6.2 REVENUE ANALYSIS
18.6.3 GEOGRAPHIC PRESENCE
18.6.4 PRODUCT PORTFOLIO
18.6.5 RECENT DEVELOPEMENTS
18.7 TEVA PHARMACEUTICALS INDUSTRIES INC.
18.7.1 COMPANY OVERVIEW
18.7.2 REVENUE ANALYSIS
18.7.3 GEOGRAPHIC PRESENCE
18.7.4 PRODUCT PORTFOLIO
18.7.5 RECENT DEVELOPEMENTS
18.8 AGILE THERAPEUTICS
18.8.1 COMPANY OVERVIEW
18.8.2 REVENUE ANALYSIS
18.8.3 GEOGRAPHIC PRESENCE
18.8.4 PRODUCT PORTFOLIO
18.8.5 RECENT DEVELOPEMENTS
18.9 ABBOTT
18.9.1 COMPANY OVERVIEW
18.9.2 REVENUE ANALYSIS
18.9.3 GEOGRAPHIC PRESENCE
18.9.4 PRODUCT PORTFOLIO
18.9.5 RECENT DEVELOPEMENTS
18.1 BESINS HEALTHCARE
18.10.1 COMPANY OVERVIEW
18.10.2 REVENUE ANALYSIS
18.10.3 GEOGRAPHIC PRESENCE
18.10.4 PRODUCT PORTFOLIO
18.10.5 RECENT DEVELOPEMENTS
18.11 JIOVIO HEALTHCARE
18.11.1 COMPANY OVERVIEW
18.11.2 REVENUE ANALYSIS
18.11.3 GEOGRAPHIC PRESENCE
18.11.4 PRODUCT PORTFOLIO
18.11.5 RECENT DEVELOPEMENTS
18.12 SEBELA PHARMACEUTICALS
18.12.1 COMPANY OVERVIEW
18.12.2 REVENUE ANALYSIS
18.12.3 GEOGRAPHIC PRESENCE
18.12.4 PRODUCT PORTFOLIO
18.12.5 RECENT DEVELOPEMENTS
18.13 RAND CORPORATION
18.13.1 COMPANY OVERVIEW
18.13.2 REVENUE ANALYSIS
18.13.3 GEOGRAPHIC PRESENCE
18.13.4 PRODUCT PORTFOLIO
18.13.5 RECENT DEVELOPEMENTS
18.14 SYNAPSE
18.14.1 COMPANY OVERVIEW
18.14.2 REVENUE ANALYSIS
18.14.3 GEOGRAPHIC PRESENCE
18.14.4 PRODUCT PORTFOLIO
18.14.5 RECENT DEVELOPEMENTS
18.15 DUCHESNAY USA
18.15.1 COMPANY OVERVIEW
18.15.2 REVENUE ANALYSIS
18.15.3 GEOGRAPHIC PRESENCE
18.15.4 PRODUCT PORTFOLIO
18.15.5 RECENT DEVELOPEMENTS
18.16 NOVARTIS AG
18.16.1 COMPANY OVERVIEW
18.16.2 REVENUE ANALYSIS
18.16.3 GEOGRAPHIC PRESENCE
18.16.4 PRODUCT PORTFOLIO
18.16.5 RECENT DEVELOPEMENTS
18.17 SIEMENS HEALTHCARE
18.17.1 COMPANY OVERVIEW
18.17.2 REVENUE ANALYSIS
18.17.3 GEOGRAPHIC PRESENCE
18.17.4 PRODUCT PORTFOLIO
18.17.5 RECENT DEVELOPEMENTS
18.18 BAYER AG
18.18.1 COMPANY OVERVIEW
18.18.2 REVENUE ANALYSIS
18.18.3 GEOGRAPHIC PRESENCE
18.18.4 PRODUCT PORTFOLIO
18.18.5 RECENT DEVELOPEMENTS
18.19 MERCK SHARP & DOHME CORP
18.19.1 COMPANY OVERVIEW
18.19.2 REVENUE ANALYSIS
18.19.3 GEOGRAPHIC PRESENCE
18.19.4 PRODUCT PORTFOLIO
18.19.5 RECENT DEVELOPEMENTS
18.2 SANOFI
18.20.1 COMPANY OVERVIEW
18.20.2 REVENUE ANALYSIS
18.20.3 GEOGRAPHIC PRESENCE
18.20.4 PRODUCT PORTFOLIO
18.20.5 RECENT DEVELOPEMENTS
18.21 RECKITT BENCKISER GROUP PLC
18.21.1 COMPANY OVERVIEW
18.21.2 REVENUE ANALYSIS
18.21.3 GEOGRAPHIC PRESENCE
18.21.4 PRODUCT PORTFOLIO
18.21.5 RECENT DEVELOPEMENTS
18.22 FEMTEC HEALTH
18.22.1 COMPANY OVERVIEW
18.22.2 REVENUE ANALYSIS
18.22.3 GEOGRAPHIC PRESENCE
18.22.4 PRODUCT PORTFOLIO
18.22.5 RECENT DEVELOPEMENTS
18.23 BLOOMLIFE
18.23.1 COMPANY OVERVIEW
18.23.2 REVENUE ANALYSIS
18.23.3 GEOGRAPHIC PRESENCE
18.23.4 PRODUCT PORTFOLIO
18.23.5 RECENT DEVELOPEMENTS
18.24 NUVO GROUP
18.24.1 COMPANY OVERVIEW
18.24.2 REVENUE ANALYSIS
18.24.3 GEOGRAPHIC PRESENCE
18.24.4 PRODUCT PORTFOLIO
18.24.5 RECENT DEVELOPEMENTS
18.25 OVIA HEALTH
18.25.1 COMPANY OVERVIEW
18.25.2 REVENUE ANALYSIS
18.25.3 GEOGRAPHIC PRESENCE
18.25.4 PRODUCT PORTFOLIO
18.25.5 RECENT DEVELOPEMENTS
18.26 SERA PROGNOSTICS
18.26.1 COMPANY OVERVIEW
18.26.2 REVENUE ANALYSIS
18.26.3 GEOGRAPHIC PRESENCE
18.26.4 PRODUCT PORTFOLIO
18.26.5 RECENT DEVELOPEMENTS
18.27 JANITRI
18.27.1 COMPANY OVERVIEW
18.27.2 REVENUE ANALYSIS
18.27.3 GEOGRAPHIC PRESENCE
18.27.4 PRODUCT PORTFOLIO
18.27.5 RECENT DEVELOPEMENTS
18.28 GYNISUS
18.28.1 COMPANY OVERVIEW
18.28.2 REVENUE ANALYSIS
18.28.3 GEOGRAPHIC PRESENCE
18.28.4 PRODUCT PORTFOLIO
18.28.5 RECENT DEVELOPEMENTS
19 CONCLUSION
20 QUESTIONNAIRE
21 ABOUT DATA BRIDGE MARKET RESEARCH
